Literature DB >> 11993688

Pancreatic neuroendocrine neoplasms: a current summary of diagnostic, prognostic, and differential diagnostic information.

M R Wick1, F M Graeme-Cook.   

Abstract

Pancreatic endocrine tumors (PETs) continue to be challenging diagnostic and prognostic lesions in surgical pathology and clinical medicine. These neoplasms can be graded into 1 of 3 tiers, based on histologic characteristics in likeness to epithelial neuroendocrine tumors in other anatomic sites. However, grade 1 tumors are by far the most common and are the most difficult to prognosticate. The most helpful features by which to gauge the behavior of such lesions include size (3 cm or larger); mitotic activity (2 or more mitoses per 10 high-power [x400] microscopic fields); marked nuclear atypia, especially with atypical mitoticfigures; predominant tumor synthesis of gastrin, vasoactive intestinal polypeptide, somatostatin, glucagon, calcitonin, or adrenocorticotropic hormone; complete nonfunctionality of the tumor at an immunohistochemical level; or invasion of blood vessels, nerves, or adjacent organs by the neoplasm. Differential diagnosis of PETs includes lesions such as solid-pseudopapillary neoplasms, acinar carcinomas, metastatic neuroendocrine tumors, and plasmacytomas.

Entities:  

Mesh:

Year:  2001        PMID: 11993688     DOI: 10.1309/9DVM-V8C4-JFL0-BCLY

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

1.  Pathological differential diagnosis of solid-pseudopapillary neoplasm and endocrine tumors of the pancreas.

Authors:  Bao-An Liu; Zhuo-Ming Li; Zhan-San Su; Xiao-Ling She
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

2.  The impact of preoperative endoscopic ultrasound on the surgical management of pancreatic neuroendocrine tumours.

Authors:  Fahad Alsohaibani; David Bigam; Norman Kneteman; A M James Shapiro; Gurpal Singh Sandha
Journal:  Can J Gastroenterol       Date:  2008-10       Impact factor: 3.522

3.  Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms.

Authors:  Michael G House; James G Herman; Ming Zhou Guo; Craig M Hooker; Richard D Schulick; Keith D Lillemoe; John L Cameron; Ralph H Hruban; Anirban Maitra; Charles J Yeo
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

Review 4.  Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining.

Authors:  Mina Jamali; Runjan Chetty
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

5.  Molecular pathology of pancreatic neuroendocrine tumors.

Authors:  Mingyi Chen; Michael Van Ness; Yangtong Guo; Jeffrey Gregg
Journal:  J Gastrointest Oncol       Date:  2012-09

6.  Prognostic significance of cytokeratin 19 expression in pancreatic neuroendocrine tumor: A meta-analysis.

Authors:  Dong Cen; Jiang Chen; Zheyong Li; Jie Zhao; Xiujun Cai
Journal:  PLoS One       Date:  2017-11-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.